Innovator IBD 50 ETF (NYSEARCA:FFTY – Get Free Report) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 22,782 shares, a decrease of 55.5% from the June 15th total of 51,245 shares. Based on an average trading volume of 35,607 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.1% of the shares of the company are sold short.
Innovator IBD 50 ETF Trading Down 0.4%
Shares of FFTY traded down $0.16 during midday trading on Wednesday, reaching $39.57. The stock had a trading volume of 15,644 shares, compared to its average volume of 68,179. The firm has a 50 day simple moving average of $41.04 and a 200-day simple moving average of $38.35. Innovator IBD 50 ETF has a one year low of $31.61 and a one year high of $44.08. The firm has a market cap of $85.08 million, a PE ratio of 30.34 and a beta of 1.45.
Hedge Funds Weigh In On Innovator IBD 50 ETF
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AlphaCore Capital LLC bought a new stake in Innovator IBD 50 ETF in the fourth quarter valued at approximately $32,000. International Assets Investment Management LLC bought a new stake in Innovator IBD 50 ETF in the 4th quarter valued at $35,000. Simplex Trading LLC acquired a new stake in Innovator IBD 50 ETF during the 4th quarter valued at $41,000. Advisory Services Network LLC acquired a new stake in Innovator IBD 50 ETF during the 3rd quarter valued at $43,000. Finally, Kestra Advisory Services LLC bought a new position in Innovator IBD 50 ETF during the fourth quarter worth $72,000.
About Innovator IBD 50 ETF
The Innovator IBD 50 ETF (FFTY) is an exchange-traded fund that is based on the IBD 50 index. The fund tracks an index of 50 US-listed stocks with aggressive growth characteristics. Holdings are selected based on fundamental and technical rankings FFTY was launched on Apr 9, 2015 and is managed by Innovator.
Further Reading
- Five stocks we like better than Innovator IBD 50 ETF
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Innovator IBD 50 ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovator IBD 50 ETF and related companies with MarketBeat.com's FREE daily email newsletter.
